Obesity Clinical Trials

Find Obesity Clinical Trials Near You

Dietary Peanut Intake and Nutrition-Related Outcomes in Individuals Using GLP-1 Receptor Agonists: A Randomized Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement, Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study will look at how eating peanuts every day might affect participants weight, how healthy their diet is, and how they feel when eating. Investigators want to see if adding peanuts to meals for 12 weeks helps participants feel fuller, have more energy, and improve body composition. The study will include adults who have been taking GLP-1 medicines like semaglutide or tirzepatide for at least three months. Investigators also want to see if eating peanuts improves overall diet quality and health markers like tiredness and certain levels in blood.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: t
View:

• Individuals with a BMI ≥30 kg/m2 or with a BMI ≥27 kg/m2 with at least one weight-related comorbidity who have been using semaglutide or tirzepatide for a clinical indication or at least 6 months

Locations
United States
Ohio
University Hospitals Cleveland Medical Center
RECRUITING
Clevland
Contact Information
Primary
Ian Neeland, MD
Ian.Neeland@UHhospitals.org
216-844-5965
Backup
Abigail Raffner, PhD, RD, LD
Abigail.Raffner@UHhospitals.org
216-368-0756
Time Frame
Start Date: 2026-04-20
Estimated Completion Date: 2027-12
Participants
Target number of participants: 64
Treatments
Experimental: Peanut Group
Participants in this group will eat 2 ounces, or 53 grams of dry-roasted, lightly salted (low sodium) each day along with their regular diet.
Active_comparator: No Peanut Group
Participants in this group will continue eating regular diet without peanuts.
Related Therapeutic Areas
Sponsors
Leads: Ian J. Neeland, MD

This content was sourced from clinicaltrials.gov